Related Experiment Video
Updated: Oct 22, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Ototoxicity and Teprotumumab
Julie Highland1, Steven Gordon1, Deepika Reddy2
1Division of Otolaryngology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Objectives:
Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea. In clinical trials, 5 participants reported self-limited audiologic symptoms but there are no objective data in the literature. The aim of this report is to describe one of the first known cases of teprotumumab-induced irreversible sensorineural hearing loss.
Methods:
Case report at a tertiary referral center.
Results:
A 61 year old female with Graves ophthalmopathy presented with bilateral hearing loss, sound distortion, and tinnitus following treatment with teprotumumab. Audiogram showed mild sloping to moderately-severe sensorineural hearing loss. Repeat audiometry obtained 4 months after cessation of teprotumumab and treatment with oral corticosteroids was unchanged.
Conclusions:
This is one of the first descriptive cases of ototoxicity resulting in irreversible sensorineural hearing loss in the setting of treatment with teprotumumab. Periodic audiologic evaluations should be recommended to patients on teprotumumab.
Related Concept Videos
Teratogenicity
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Affecting Factors
Tumor Immunotherapy
Desensitization and Tachyphylaxis

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)